Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01276236 · ClinicalTrials.gov registry record · Phase 2
Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)
A Phase 2 study of Kaposi's Sarcoma, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT01276236: Completed Phase 2 study of Kaposi's Sarcoma, sponsored by University of California, San Francisco.
NCT01276236 is a Phase 2 study of Kaposi's Sarcoma that has completed, run by University of California, San Francisco. The registered enrollment target is 13 participants, below the 452-participant average among 3 other Kaposi's Sarcoma trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01276236, a Phase 2 study of Kaposi's Sarcoma, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this pilot study is to determine whether Maraviroc is effective in the treatment of Kaposi's Sarcoma (KS), when it does not remit with standard antiretroviral drug therapy.
Primary Outcome
To assess improvements in disease, up to five bi-dimensionally measurable cutaneous KS lesions were selected as marker lesions. The collective surface area of the marker lesions was evaluated over the course of the study for either an increase or decrease in the total surface area of lesions using the modified AIDS Clinical Trials Group (ACTG) Oncology Committee Staging Criteria.
Conditions Studied
Interventions
- DRUG Maraviroc
Study Locations (1)
California
- San Francisco General Hospital, Clinical Trials Unit - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2011-03-09 |
| Est. Completion | 2015-04-30 |
| Phase | Phase 2 |
What the finished NCT01276236 record still lists
NCT01276236 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 452-participant average among 3 other Kaposi's Sarcoma trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Kaposi's Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which Maraviroc is the first listed.
NCT01276236 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01276236 about?
NCT01276236 is a clinical study titled "Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)". The purpose of this pilot study is to determine whether Maraviroc is effective in the treatment of Kaposi's Sarcoma (KS), when it does not remit with standard antiretroviral drug therapy.
What is the current status of trial NCT01276236?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2011-03-09. Estimated completion is 2015-04-30.
What conditions does trial NCT01276236 study?
This clinical trial studies the following conditions: Kaposi's Sarcoma.
What interventions are being tested in trial NCT01276236?
The interventions under investigation include: Maraviroc (DRUG).
Who is sponsoring clinical trial NCT01276236?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01276236 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kaposi's Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer
RECRUITING
-
Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease
RECRUITING
-
Twins Study of Gene Therapy for HIV Infection
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI